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with type 1 diabetes was performed. METHODS: The search was performed between 
January 1, 2000 and December 1, 2009 via Embase, Medline, the Cochrane Library, 
the databases of German Medical Science and of DAHTA (Deutsche Agentur für 
Health Technology Assessment), and abstract books of relevant scientiﬁ c congresses. 
The inclusion of retrieved studies was based on predeﬁ ned criteria. The included 
studies were assessed according to established methodological and quality aspects. 
RESULTS: A total of four health-economic evaluations from four different countries 
were included: two modeling studies, comprising one cost-utility analysis (CUA) and 
one cost-minimization analysis (CMA), as well as two claims data analyses, both 
CMAs. Two of the CMAs show an economic advantage in favour of GLA vs. DET 
and the third CMA showed cost neutrality between the basal insulin analogues. The 
CUA showed an economic advantage for DET. CONCLUSIONS: Despite some dif-
ferences concerning evaluation methods (CUA or CMA), data sources (randomized 
controlled trial, claims data) and country speciﬁ c conditions (pricing and reimburse-
ment situation) the identiﬁ ed health economic analyses showed high conformity con-
cerning the target parameters. Two of the studies showed an advantage in favour of 
GLA compared to DET, the extent of which depended on the respective design of the 
health economic analysis chosen. a systematic review to compare the health economic 
outcomes of GLA and NPH-insulin was done separately. ACKNOWLEDGMENT: 
This study was supported by Sanoﬁ -Aventis Deutschland GmbH, Berlin, Germany.
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OBJECTIVES: In these cost-utility analyses CORE Diabetes Model and LEAD-1 and 
LEAD-6 trials data were used to compare liraglutide (a glucagon-like peptide-1 recep-
tor agonist) to rosiglitazone, both in combination with glimepiride, and to exenatide, 
both with metformin and/or sulfonylurea. METHODS: The analyses were performed 
from the health care services payer’s perspective. In the base-case analysis a time 
horizon of 20 years has been chosen. The analysis compared patients treated with 
liraglutide 1.2 mg or rosiglitazone 4 mg (LEAD-1) or liraglutide 1.8 mg or exenatide 
10 μg b.i.d. (LEAD-6). The analysis used health state utility values derived from lit-
erature. The cost of treatment and complications were based on ofﬁ cially published 
sources for medicines prices (www.mh.government.bg), for hospital charges (www.
nhif.bg) and veriﬁ ed by expert opinion survey (1 BGN = 0.51 EUR). RESULTS: 
QALYs increased with liraglutide 1.2 mg by 0.252 (SD 0.129) years (LEAD-1). Total 
costs increased by BGN7722 (c3948) resulting in an incremental cost per QALY 
gained of BGN30,674 (c15,684). Based on LEAD-6 trial data liraglutide 1.8 mg 
resulted in increase of 0.151 (SD 0.124) QALYs. Total costs increased by BGN4151 
(c2122) with incremental cost BGN27,404 (c14,012) per QALY. CONCLUSIONS: 
In Bulgarian health care system settings liraglutide added to standard treatment have 
been shown to be cost-effective in comparison with rosiglitazone and exenatide for 
type 2 diabetes.
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OBJECTIVES: This is a cost-utility analysis of saxagliptin (treatment group) vs. thia-
zolidinediones (control group) as add-on therapy in type 2 diabeties (T2D) patients 
not achieving appropriate glycaemic control with metformin, from the Brazilian 
private health system (PHS) perspective. METHODS: A discrete event simulation 
model based on UKPDS68 study was developed in order to simulate 40 years for a 
cohort of 1000 patients. Safety and efﬁ cacy data were obtained from a systematic 
review and meta-analysis of published literature. Epidemiological and costing data 
were obtained from DIAPS79, an outcome study of the treatment patterns and costs 
of T2D patients in the Brazilian PHS. Pharmaceutical costs were based on Brazilian 
ofﬁ cial factory price. Insulin plus metformin was deﬁ ned as rescue therapy. An annual 
discount rate of 5% was applied to both costs and beneﬁ ts. Deterministic and proba-
bilistic sensitivity analyses were conducted to assess the robustness of the results. 
RESULTS: According to the model, the lipid proﬁ le beneﬁ ts from thiazolidinediones 
did not translate into long-term vascular beneﬁ ts when compared to saxagliptin 
(vascular fatal events risk reduction of −0.0034 vs. pioglitazone and −0.0053 vs. 
rosiglitazone). Saxagliptin was dominant when compared to both pioglitazone and 
rosiglitazone as the add-on therapy of choice to metformin (costs savings per patient 
of R$3.874 vs. rosiglitazone and R$3.996 vs. pioglitazone; incremental 0.13 QALY 
per patient vs. pioglitazone and 0.14 QALY per patient vs. rosiglitazone). In the 
deterministic sensitivity analysis, HbA1c level was the most impactful parameter in 
the model, but saxagliptin remained the dominant option in all cases. In the probabi-
lisitc sensitivity analysis, saxagliptin had a greater than 90% probability of being 
cost-effective for a willingness-to-pay of zero. CONCLUSIONS: Saxagliptin is associ-
ated with lower costs and increased quality-adjusted life expectancy compared to thia-
zolidinediones as add-on therapy in T2D patients failing to achieve adequate glycaemic 
control on metformin monotherapy. 
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OBJECTIVES: Our aim was to assess cost-utility ratios of liraglutide, a GLP-1 recep-
tor agonist, in comparison with rosiglitazone, glimepiride and exenatide for type 2 
diabetes in Romanian health care system settings. METHODS: The CORE Diabetes 
Model and clinical data from LEAD-1 (liraglutide vs. rosiglitazone, both with 
glimepiride, 1st case), LEAD-2 (liraglutide vs. glimepiride, both with metformin, 2nd 
case) and LEAD-6 trial (liraglutide vs. exenatide, both with metformin and/or sulfo-
nylurea, 3rd case) trials were used. The health care services payer’s perspective and 
20-year time horizon have been chosen. Health state utility values and cost date were 
based DRG Data from “Center for Research and Evaluation of Healthcare Services,” 
Romania, CaNaMed National Catalog of Medicines Prices (ofﬁ cial tariff lists) and 
expert opinion. RESULTS: In the 1st case QALYs increased by 0.201 (SD 0.105) years 
with liraglutide 1.2 mg and by 0.231 (SD 0.107) years with liraglutide 1.8 mg. Total 
costs increased by c3266 and c5378 resulting in an incremental cost per QALY gained 
of c16,209 and c23,282, respectively. In the 2nd case, liraglutide 1.2 mg resulted in 
increase of 0.155 (SD 0.099) QALYs and liraglutide 1.8 mg 0.170 (SD 0.146) QALYs 
with incremental cost per QALY gained of EUR 29,909 and EUR 38,830, respectively. 
In the 3rd case QALYs increased by 0.125 (SD 0.102) years with liraglutide 1.8 mg, 
total costs increased by c1898, an incremental cost was c15,123 per QALY. CON-
CLUSIONS: Based on efﬁ cacy data from clinical trials and validated model liraglutide 
has been shown to be cost-effective when compared with rosiglitazone, glimepiride 
and exenatide for the treatment of type 2 diabetes.
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OBJECTIVES: Persistence with respect to injectable therapy in type 2 diabetes is 
known to impose a challenge to patients. One potential explanation is aversion to 
injection and risk of hypoglycemic events. Insulin analogues have shown in clinical 
trials to reduce the risk of hypoglycemic events versus human insulins, and insulin 
injection using a pen device is generally perceived as less burdensome than administra-
tion via vial and syringe. METHODS: This retrospective data analysis compared 
persistence between two types of basal insulin and administration: Neutral protamine 
hagedorn, NPH, administered by vial and syringe and insulin detemir, IDet, adminis-
tered by FlexPen®. Data were derived from health care claims between 2004 and 2009 
from a large national US payer and included type 2 diabetes patients that initiated 
either IDet FlexPen® or NPH in vials without any prescription ﬁ lls for any insulin in 
the previous 12 months. Patients were deﬁ ned as being persistent to therapy as long 
as they ﬁ lled their prescription within the 80th percentile of days between ﬁ lls adjusted 
to reﬂ ect differences in pack sizes. RESULTS: The IDet FlexPen® cohort (n = 1082) 
and the NPH vial cohort (n = 794) were of similar age (54.06 vs. 53.13, P = 0.134), 
but IDet FlexPen® had a lower proportion of female patients than NPH vials (44% 
vs. 55%, P < 0.001) and fewer treatment naïve patients (no pre-index OADs) (9% vs. 
45%, P < 0.001). Persistency to therapy at 12 months after initiation was 23% and 
13% (P < 0.001) for IDet FlexPen® and NPH vials, respectively. Average days of 
persistence was 167 days for the IDet FlexPen® cohort and 123 days for NPH vials 
(P < 0.001). CONCLUSIONS: Persistence to insulin therapy among type 2 diabetes 
patients could be improved. This study suggests that insulin persistency may be 
improved by initiating insulin using therapies associated with lower risk of hypogly-
cemic events and administering it in a pen.
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OBJECTIVES: Adherence interventions (AI) are an important part of the health care 
provision situation on the ground. For ethical, clinical and health economic reasons, 
it is vital to identify methodological characteristics of successful AI. The aim of this 
review is to do this for AI focused on oral anti-diabetics (Diabetes type II). METHODS: 
A comprehensive review of Diabetes type II AI effectiveness studies was conducted 
[Strings: (oral hypoglycemic agents; oral anti-diabetic medications; diabetes; hypergly-
cemia; Biguanide; Metformin; Potassium channel inhibitors; Dipeptidyl peptidase-4 
inhibitors) and (improvement; enhancement; pharmacy, pharmacist; doctors; interven-
tions; programs; reminder; prevention; patient education)]. Only interventions aiming 
to improve medication adherence/persistence were included. RESULTS: A total of 
6977 contributions were identiﬁ ed; after detailed examination by two reviewers 15 
publications evaluating 19 different AI were included. 10 AI were able to improve the 
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adherence/persistence and eight were able to improve the blood glucose levels of 
patients (double counting in three cases); ﬁ ve had no effect at all. Four dimensions of 
the methodological quality of AI programs were identiﬁ ed: 1) measurement of adher-
ence/persistence/clinical outcomes, 2) measurement of NA/NP causes, 3) use of effec-
tive/validated intervention measures; and 4) effective program evaluation. The authors 
deﬁ ned 5 detailed methodological requirements per dimension and, based on this, 
developed a corresponding scoring model (MIN Score 0, MAX score 20). All 19 AI 
programs were evaluated in the scoring model (average score 8.05): • Score <5: 3 
AI—no adherence/blood glucose level improvement; • Score 5–9: 8 AI—6 with 
improvement in both adherence and/or blood glucose levels; • Score >9: 8 AI—all 
improved adherence and/or blood glucose levels. CONCLUSIONS: The scoring model 
provides a starting point for the methodical evaluation of AI. However, further devel-
opment and testing of both the elements and construction is needed for medical indica-
tions other than diabetes type II.
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OBJECTIVES: To translate the MMAS into the Malaysian language, and to examine 
the psychometric properties of the Malaysian version of the MMAS among patients 
with type 2 diabetes, including its validity and reliability. METHODS: After obtaining 
permission, a standard “forward-backward” translation procedure was used to create 
the Malaysian version of the MMAS from the original English version. a convenience 
sample of 223 outpatients with type 2 diabetes was identiﬁ ed between May and Sep-
tember, 2009. All data were collected from the Penang General Hospital, Penang, 
Malaysia. Instruments consisted of the Malaysian version of MMAS, the Malaysian 
version of the old four-item Morisky scale and a sociodemographic questionnaire. 
Medical records were reviewed for hemoglobin A1C (HbA1C) levels and other clinical 
data. Reliability was tested for internal consistency using Cronbach’s α coefﬁ cient. 
Validity was conﬁ rmed using convergent and known group validity. RESULTS: 
Employing the recommended scoring method, the mean ± SD of MMAS scores was 
6.13 ± 1.72. Moderate internal consistency was found, (Cronbach’s α = 0.675), the 
test-retest reliability value by using Spearman’s rank correlation was 0.816 (P < 
0.001). a positive correlation between the eight- and four-item MMAS was found (r 
= 0.792; P < 0.01). For known group validity, a signiﬁ cant relationship between 
MMAS categories and HbA1c categories (χ2 = 20.261; P ≥ 0.001) was found. The 
MMAS sensitivity and speciﬁ city, with positive and negative predictive values were 
77.61%, 45.37%, 46.84% and 76.56%, respectively. CONCLUSIONS: The MMAS 
can be used for medication adherence measurement in diabetes. The ﬁ ndings of this 
validation study indicate that the Malaysian version of the MMAS is a reliable and 
valid measure of medication adherence which can now be used in clinical practice.
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OBJECTIVES: The last decade several studies have proven that lifestyle interventions 
can be effective for people with or at risk for diabetes. Because effectiveness of preven-
tive interventions is affected by non-participation (adherence), it is important to 
understand factors inﬂ uencing people’s willingness to participate in a lifestyle interven-
tion. Therefore, the aim of this exploratory analysis is to examine which factors of a 
lifestyle program inﬂ uence its valuation and willingness to participate. METHODS: 
We used conjoint analysis to empirically examine associations between the factors that 
inﬂ uence participation and participants’ valuation of an intervention and participants’ 
willingness to participate in a lifestyle intervention. For this purpose participants 
received a questionnaire with four hypothetical lifestyle interventions. They were 
asked to value the hypothetical scenarios with a grade from “1” to “10” and further-
more they were asked if they would be willing to participate in these hypothetical 
programs. Linear and logistic regression techniques were used for the analyses. 
RESULTS: The factors “group activity,” “counselling,” and “receiving money” were 
positively associated with the scores of the valuation of the programmes. Logistic 
regression analysis showed that money was the only factor that was independently 
associated with respondents’ willingness to participate in a lifestyle intervention. 
Subgroup analysis showed that receiving an amount of money was not associated with 
willingness to participate, but having to pay is negatively associated with participation 
in the lifestyle intervention. CONCLUSIONS: It appeared that only ﬁ nancial disincen-
tives were independently associated with willingness to participate in a lifestyle inter-
vention. Our conjoint analysis results suggest that ﬁ nancial incentives, in the form of 
bonuses, cannot be used to encourage people to participate in lifestyle interventions. 
Financial incentives, in the form of payments might however discourage participation, 
regardless of the content of the program.
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OBJECTIVES: To present HRQL data from a previously presented survey on T2D 
patients’ perceived quality of care in Stockholm, Sweden. METHODS: A postal survey 
including EQ-5D was distributed to 1000 members of the Stockholm Diabetic Patient 
Association and 1000 patients from ﬁ ve primary health care centers. Patients were 
randomly selected, >18 years, having a diabetes diagnosis. Analysis of variance was 
used to test the statistical hypothesis that patients within each subgroup had equal 
mean utility. RESULTS: Response rate was 65% (1319/2000 questionnaires). T2D 
diagnose was reported for 961 respondents of which 858 completed the EQ-5D 
questionnaire. Mean age 69 years, 48.5 % female, BMI 28.4 kg/m2, mean duration 
of T2D 11.3 years. Overall, the mean (SD) utility was 0.765 (0.260) and the current 
health status reported on the VAS scale was 0.727 (0.189). Patients without any 
hypoglycemic episode the previous month had a utility of 0.799 while those with 1, 
2–5 or >5 episodes reported 0.774, 0.687 and 0.633, respectively. More than one 
hypoglycemic episode resulted in signiﬁ cantly lower utility compared to none or only 
one episode (P < 0.0001). The utility of obese patients, 0.704, was signiﬁ cantly lower 
than for patients of normal weight, 0.806, or overweight, 0.790 (P < 0.0001). The 
utility of patients not considering themselves responsible for the management of their 
T2D was signiﬁ cantly lower, 0.608, compared to patients taking a limited, 0.774, or 
full, 0.759, responsibility (P = 0.0005). Patients considering themselves having insuf-
ﬁ cient knowledge to cope with their T2D reported a lower utility, 0.689, compared 
to patients with sufﬁ cient knowledge, 0.789 (P < 0.0001). Male respondents had a 
higher utility, 0.796, compared to females, 0.731 (P = 0.0002). CONCLUSIONS: 
Experience of hypoglycemic episodes, obesity, gender, patients’ perception of personal 
responsibility and perceived knowledge about type 2 diabetes has signiﬁ cant impact 
on health related quality of life in patients with type 2 diabetes.
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OBJECTIVES: Cost-utility analysis in diabetes requires utility estimates for diabetic 
complications. Models frequently rely on UKPDS data. UK requirements for prefer-
ence elicitation have changed since UKPDS publication. We conducted a systematic 
review of the literature to identify utility values for diabetes complications suitable for 
use in Health Technology Assessment (HTA). METHODS: A systematic search of 
online databases was conducted using key words relating to diabetes, major complica-
tions, utility assessment and quality of life. Reference lists of identiﬁ ed citations were 
reviewed. Studies reporting utility single-index measures in patients with any of 33 
pre-speciﬁ ed diabetes related states were included: states considered were diabetic 
complications and adverse events associated with anti-diabetic therapies (AEs). Papers 
were qualitatively assessed: criteria included relevance of studied population to Type 
1 or Type 2 diabetes, sample size, methodological quality and consistency with current 
UK HTA guidelines. Comorbidity is common in diabetes: methodology papers 
addressing combination of utility values were identiﬁ ed in a structured search and 
reviewed. RESULTS: The search returned 3024 hits, 169 articles were reviewed and 
32 publications were identiﬁ ed as suitable for review. Utility or disutility values suit-
able for UK HTA were obtained for 23 diabetes states. For 10 complications, including 
late stage renal disease and some AEs, no utility value were identiﬁ ed that met UK 
HTA criteria. There is no consensus in the literature on how utility measures should 
be combined in patients with more than one complication. CONCLUSIONS: We 
identiﬁ ed a set of utility values suitable for economic analysis for HTA in diabetes. 
To further inform UK HTA, additional research should create robust utility values for 
diabetic renal disease, and evaluate the empirical accuracy of alternative methods of 
combining utility values in patients with multiple complications.
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OBJECTIVES: The study is to measure the health-related quality of life (HRQOL) in 
type 2 diabetes mellitus (T2DM) patients with oral anti-diabetic drugs (OADs) therapy 
using the Chinese version of EQ-5D, and examine their health status. METHODS: 
The study was a cross-sectional survey conducted at 75 hospitals in nine cities in 
China. There were 9577 T2DM patients administered with OADs therapy completed 
the questionnaires. The survey period was from December 3rd, 2008 to July 31st, 2009. 
Patients evaluated their health status using ﬁ ve dimensions (5D) and a visual analog 
scale (VAS). Descriptive statistics was used to describe patients’ demographic charac-
teristics, duration of the disease, the frequency of 5D responses and VAS score. STATA 
9.2 was used for the analyses. RESULTS: The mean age of patients (±SD) was 59.5 
± 12.7 years. 51.1% were male. The mean body mass index (±SD) was 24.3 ± 3.4 kg/
m2. The mean duration of disease (±SD) was 7.9 ± 6.3 years. For the ﬁ ve dimensions 
